Early trial aims to tame Tough-to-Treat lymphomas with drug cocktail
NCT ID NCT01695941
Summary
This early-stage study is testing a combination of three drugs—alisertib, bortezomib, and rituximab—in patients whose mantle cell or low-grade B-cell lymphoma has returned or stopped responding to other treatments. The main goal is to find the safest and most effective doses of the new drugs when used together. Researchers will also check if the treatment helps shrink the cancer and how long the benefit lasts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
Conditions
Explore the condition pages connected to this study.